Can we select NSCLC patients for immune checkpoint therapy?

32 / 38

PS ≥ 2 and ICI efficacy
IFCT-1502 CLINIVO
Salloum – Cancer 2011 * Molinier – WCLC 2017 * Popat – ESMO 2017
PS ≥ 2 is reported in up to 25% of contemporary cohorts of NSCLC patients
Check Mate 171 N=98 Sq-NSCLC PS 2 patients. RR: 11%. OS 5.4 mo. 46% AE’s (6% g3)
OS= 3.4 mo.